Avinash Kale to Oversee Trinity Biotech’s CGM Technology

Trinity Biotech plc has appointed Avinash Kale as Continuous Glucose Monitor (CGM) Programme director. His appointment is intended to help the company advance its recently acquired CGM technology and drive its innovation and development to bring a comprehensive CGM solution to the global market.

“We are excited to welcome Avinash to Trinity Biotech, where he will be instrumental in advancing our mission of introducing intelligent wearable biosensors, including CGMs, into markets all around the globe. I believe that Avinash will bring a new level of knowledge and experience in the design and large-scale manufacture of advanced medtech devices to this project,” Trinity Biotech CEO John Gillard said. “Our plan is to expand the usage of this technology across the hundreds of millions of people whose health is impacted by diabetes by introducing a high-quality, more affordable and lower waste CGM. Our CGM platform leverages our acquisition of European regulatory approved CGM technology and our lengthy experience in global diabetes management solutions, where we currently support approximately 10 million people with diabetes annually. We are building a team of top talent to execute on our plans and investing in this business so as to maximize shareholder value creation.”

A seasoned medtech R&D, PMO, and innovation leader with extensive global industry experience, Kale joined Trinity Biotech’s team in Ireland from his previous employer, Philips Healthcare. His career spans roles of increasing responsibility across Fortune 500+ firms Philips Healthcare Netherlands, Dell China, TATA India, and Europe based scale-ups and startups. Kale has held key leadership positions, such as global director of Engineering; chief technology officer; global Medical Device PMO; and head of Embedded Systems, R&D Program Management, and Systems Engineering by steering global partners eco-system and teams across multiple sites and delivering cutting-edge solutions that drive meaningful innovations. Throughout his career, Kale has been a catalyst for impactful initiatives, including global product design and development, Lean R&D, program leadership, business integration, emerging market initiatives, R&D process innovation, product innovation, enabling technologies implementation, and transformation and change management, demonstrating his expertise in the end-to-end medical device solution life cycle.

Kale earned a degree in electronics and telecommunications from Pune University, India, and has successfully completed the Leading Digital Transformation in Healthcare Executive Programme from Harvard Medical School.

“I am thrilled to begin this new chapter and to embark on this pivotal and challenging role, joining the Trinity team dedicated to making this needle-free CGM solution accessible to patients worldwide. This initiative promises a fast-paced, patient-centric, and innovative environment, with a strong sense of urgency to assist underserved patients affected by diabetes in improving their quality of life. I’m very excited to contribute to this endeavor,” Kale stated.